Miniatura

Fitxers

canton22mar2023.pdf (578.5 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-03-22

Llicència de publicació

cc-by-nc (c) García Fernández, Sergio et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224625

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.37201/req/007.2023

Resum

Objectives. To determine susceptibility to the novel beta-lactam/beta-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 - 2020. Methods. Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. Results. In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. Conclusions. Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients' location (ICU or non-ICU scenarios).

Matèries

Medicaments antibacterians, Antibiòtics, Microbiologia farmacèutica

Matèries (anglès)

Antibacterial agents, Antibiotics, Pharmaceutical microbiology

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GARCÍA FERNÁNDEZ, Sergio, CALVO, Jorge, CERCENADO, Emilia, SUÁREZ BARRENECHEA, Ana isabel, FERNÁNDEZ BILLÓN, María, CASTILLO, Francisco javier, GÁLVEZ BENÍTEZ, Lydia, TUBAU, Fe, FIGUEROA CERÓN, Ruth esther, HERNÁNDEZ CABEZAS, Alicia, GONZÁLEZ ROMO, Fernando, FARIÑAS, María carmen, GÓMEZ, Maria, DÍAZ REGAÑÓN, Jazmín, CANTÓN, Rafael. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020. _Revista Española de Quimioterapia_. 2023. Vol. 36, núm. 3, pàgs. 302-309. [consulta: 24 de gener de 2026]. ISSN: 0214-3429. [Disponible a: https://hdl.handle.net/2445/224625]

Exportar metadades

JSON - METS

Compartir registre